#AS­CO19 roundup: As­traZeneca, Mer­ck score an­oth­er Lyn­parza hit

CHICA­GO — Lyn­parza con­tin­ues to be the big can­cer drug suc­cess sto­ry that As­traZeneca CEO Pas­cal So­ri­ot so bad­ly needs. 

On Sun­day, the phar­ma gi­ant — along with their part­ners at Mer­ck — re­leased new da­ta demon­strat­ing that their lead­ing PARP in­hibitor spurred a sig­nif­i­cant in­crease in pro­gres­sion-free sur­vival among BR­CA-mu­tat­ed pan­cre­at­ic can­cer pa­tients when used as a front­line main­te­nance ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER